地诺孕素治疗复发型卵巢子宫内膜异位症的临床效果

Clinical effect of Dienogest in the treatment of recurrent ovarian endometriosis

目的探讨地诺孕素治疗复发型卵巢子宫内膜异位症(OEM)的临床效果。方法选取2019年9月—2020年3月江西省妇幼保健院收治的40例复发型OEM患者作为研究对象,采用随机数字表法将其分为对照组与观察组,每组各20例。对照组患者给予屈螺酮炔雌醇片治疗,观察组患者给予地诺孕素治疗。比较两组患者治疗前及治疗3、6个月后的月经情况、子宫内膜异位囊肿体积、痛经、慢性盆腔痛或性交痛视觉模拟量表(VAS)评分、血清糖链抗原125(CA125)、血脂水平及不良反应发生情况。结果治疗后,两组患者的月经频率正常率及月经经期正常率比较,差异无统计学意义(P>0.05)。治疗前,两组患者的囊肿体积、痛经VAS评分、盆腔痛或性交痛VAS评分、血清CA125、三酰甘油及总胆固醇比较,差异无统计学意义(P>0.05);治疗6个月后,观察组患者的囊肿体积小于对照组,痛经VAS评分、盆腔痛或性交痛VAS评分、CA125均低于对照组,差异有统计学意义(P<0.05);治疗6个月后,两组患者的三酰甘油、总胆固醇及不良反应发生率比较,差异无统计学意义(P>0.05)。结论地诺孕素可显著改善OEM患者的疼痛程度,减小囊肿体积,降低血清CA125水平,临床疗效较好。

Objective To explore the clinical efficacy of Dienogest in the treatment of recurrent ovarian endometriosis(OEM).Methods A total of 40 patients with recurrent OEM admitted to Jiangxi Maternity and Child Health Hospital from September 2019 to March 2020 were selected as the research objects and divided into the control group and the observation group by random number table method,with 20 cases in each group.Patients in the control group were treated with Drospirenone Ethinyl Estradiol Tablets,and in the observation group,patients were treated with Dienogest.The menstruation,endometriotic cyst volume,dysmenorrhea,chronic pelvic pain or dyspareunia visual analogue scale(VAS)score,serum carbohydrate antigen 125(CA125),blood lipid levels and the incidence of adverse reactions were compared between the two groups before treatment and 3 and 6 months after treatment.Results There were no statistically significant differences in the rate of normal menstrual frequency and normal menstrual period between the two groups after treatment(P>0.05).There were no statistically significant differences in volume of cysts,VAS score of dysmenorrhea,VAS score of pelvic pain or dyspareunia,serum CA125,triglyceride and total cholesterol between the two groups before treatment(P>0.05).After 6 months of treatment,the volume of cysts in the observation group was lower than that in the control group,VAS score of dysmenorrhea,VAS score of pelvic pain or dyspareunia and serum CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in triglyceride,total cholesterol and clinical adverse reactions between the two groups after six months of treatment(P>0.05).Conclusion Dienogest can significantly relieve pain,reduce the volume of cysts and serum CA125 in OEM patients,and the clinical effect is good.